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Edited by Barry HalliwellAbstract Sulforaphane (SFN) is an activator of the transcrip-
tion factor Nrf2, which plays a critical role in metabolism and
excretion of xenobiotics. Exposure of primary mouse hepato-
cytes to SFN resulted in activation of Nrf2 and signiﬁcant eleva-
tion of protein expressions responsible for excretion of arsenic
into extracellular space. Pretreatment with SFN 24 h prior to
arsenite exposure reduced not only arsenic accumulation in the
cells but also cellular toxicity of this metalloid. Therefore, our
ﬁndings indicate a potential function of SFN in reducing cellular
arsenic levels, thereby diminishing arsenic toxicity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Inorganic arsenic is a metalloid that is ubiquitously distrib-
uted in the earth’s crust. High levels of arsenic contamination
of groundwater in an endemic area of chronic arsenic poison-
ing in east Asia have led to severe environmental problems. It
is well recognized that in humans, inorganic arsenic undergoes
reduction and oxidative methylation and thus monomethyl
and dimethyl metabolites of arsenic are excreted into urine
[1,2]. Alternatively, inorganic arsenite is bound to glutathione
(GSH), which is synthesized by c-glutamylcysteine synthase
(c-GCS), by chemical and/or enzymatic processes through pre-
sumably GSH S-transferases (GSTs) to yield arsenic trigluta-
thione (As(GS)3) [3,4]. This polar metabolite is excreted into
extracellular space via multidrug resistance-associated protein
(MRP) [4,5]. Interestingly, Hayakawa et al. [6] reported re-
cently that the GSH adduct of arsenic is an intermediate for
methylarsenic, suggesting that the GSH conjugation is essen-
tial for facilitation of arsenic excretion. Because cytotoxicity
of arsenic is thought to be associated with its accumulation
in cells, it is postulated that a possible approach to chronic ar-
senic poisoning is activation of transcription factors that con-
trol proteins such as c-GCS, GSTs and transporters associated
with arsenic excretion into extracellular space.Abbreviations: SFN, sulforaphane; Nrf2, nuclear factor E2 related
factor 2; c-GCS, c-glutamylcysteine synthase; c-GCSH, c-GCS heavy
subunit; c-GCSL, c-GCS light subunit; GSH, glutathione; GST, GSH
S-transferase; MRP, multidrug resistance-associated protein
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doi:10.1016/j.febslet.2006.02.031Nuclear factor E2 related factor 2 (Nrf2) has been identiﬁed
as a transcription factor regulating proteins that participate in
metabolism and excretion of organic chemicals [7,8]. For this
reason, treatment with chemicals activating Nrf2 before expo-
sure to carcinogens has been attempted [8,9]. For example, we
found that pretreatment with an Nrf2 activator, oltipraz, re-
duced tumor incidence caused by alkyl nitrosoamine by induc-
ing phase II enzymes such as UDP-glucuronosyltransferase,
thereby decreasing tissue levels of the reactive metabolite of
N-nitrosobutyl(3-carboxypropyl)amine [10]. Sulforaphane
(SFN), a compound found in broccoli sprouts and broccoli, is
also known to be a potent Nrf2 activator and is capable of pre-
venting toxicity of organic chemicals [9,11]. To our knowledge,
however, the protective eﬀect of Nrf2 activators on arsenic-
mediated cytotoxicity has not been reported. Our rationale
was that upregulation of proteins responsible for excretion of
arsenic into extracellular space could lead to substantial reduc-
tion of steady-state levels of arsenic in cells, thereby diminishing
cellular toxicity caused by arsenic exposure. Here, we report, for
the ﬁrst time, that SFN is an eﬀective agent in reducing cellular
arsenic levels in primary mouse hepatocytes and thus the cyto-
toxicity of arsenic.2. Materials and methods
2.1. Materials
Sodium arsenite (iAs(III)) was purchased fromWako Pure Chemical
Industries, Ltd. (Osaka, Japan); SFN from LKT Laboratories (St.
Paul, MN, USA); anti-MRP1 from Alexis Biochemicals (San Diego,
CA, USA); anti-Nrf2, anti-c-GCSH, and anti-c-GCSL from Santa
Cruz Biotechnology (Santa Cruz, CA, USA); anti-GSTA1, anti-
GSTM1, and anti-GSTP1 from Oxford Biomedical Research (Oxford,
MI, USA); anti-actin from Sigma (St. Louis, MO, USA); and anti-
heme oxygenase-1 (HO-1) from Stressgen (Victoria, Canada). Anti-
GSTA4 and anti-arsenite methyltransferase (CYT19) were kindly
provided by Dr. Akira Hiratsuka (Tokyo University of Pharmacy
and Life Science, Japan) and by Dr. Yayoi Kobayashi (National Insti-
tute for Environmental Studies, Japan), respectively. All other reagents
and chemicals used were of the highest grade available.2.2. Isolation and culture of primary mouse hepatocytes
Primary hepatocytes were isolated from 6- to 9-week-old C57BL/6J
male mice by collagenase perfusion according to the method described
by Liang et al. [12] with slight modiﬁcation. Brieﬂy, the liver parenchy-
mal hepatocytes were seeded at a density of 8 · 104 cells/cm2 with Wil-
liam’s medium E containing 20 mM L-alanyl-L-glutamine, 100 U/ml
penicillin, 100 lg/ml streptomycin, 1 lg/ml insulin, 0.1 lM dexametha-
sone, and supplemented with 10% FBS. They were plated into culture
plates coated with pig type I collagen (IWAKI, Japan). The culturesblished by Elsevier B.V. All rights reserved.
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sphere of 5% CO2 and 95% air. We stimulated cells with SFN from
the 3rd day of isolation to stabilize cell response because transient
HO-1 expression was observed just after isolation of the hepatocytes.
All experiments were performed at least twice using diﬀerent cell cul-
ture preparations.
2.3. Assay of cytotoxicity
MTT assay was performed as previously described [13].
2.4. Alteration in protein levels
Western blotting analysis was performed as previously described
[14]. Nuclear fraction was prepared by using nuclear extraction reagent
(PIERCE, IL, USA) according to the manufacturer’s protocol. Crude
membrane fraction was prepared by diﬀerential centrifugation as de-
scribed by Germann et al. [15].
2.5. Measurement of intracellular GSH
Cellular GSH content was determined according to the method de-
scribed by Vignaud et al. [16] with slight modiﬁcation (HPLC-ECD).
Brieﬂy, 10 ll of samples obtained from the primary mouse hepatocytes
were loaded onto a C18 Beckman ODS column (250 mm · 4.6 mm,
i.d.) equipped with a guard column (17 mm · 4.6 mm, i.d.).
2.6. Measurement of arsenic concentrations
Cellular arsenic was measured by ICP-MS (HP4500 plus, Yokokawa
Analytical Systems, Tokyo, Japan) after digestion of those samples
with nitric acid–H2O2 as previously described [17]. Cells were plated
into 12-well culture plates.Fig. 2. SFN activates Nrf2 in primary mouse hepatocytes. (A)
Western blot analysis to detect nuclear fraction of Nrf2 after the
treatment of cells with 10 lM SFN for 0, 1, 6, 12, and 24 h. Actin was
used as an internal control. (B) Western blot analysis of Nrf2, HO-1, c-
GCSH, c-GCSL, GSTA1, GSTA4, GSTM1, GSTP1, and CYT19 in
whole cell lysates. Cells were treated with 0–10 lMSFN for 24 h. Actin
was used as an internal control. (C) Western blot analysis of MRP1.
Cells were treated with 0–10 lM SFN for 24 h. Crude membrane
fractions were used.3. Results
It has been reported that chemicals which block GSH syn-
thesis and transporters for arsenic excretion into extracellular
space cause acceleration of arsenic accumulation in cells and
thus accelerate cytotoxicity caused by arsenic [18]. Exposure
of primary mouse hepatocytes to iAs(III) resulted in a concen-
tration-dependent cytotoxicity with a LD50 value of 30 lM at
48 h after arsenic exposure. Pretreatments with buthionine sul-
foximine (BSO, c-GCS inhibitor), with ethacrynic acid (EA,
GST inhibitor), with MK-571 (MRP antagonist) caused signif-
icant enhancement of iAs(III)-mediated cytotoxicity, respec-
tively (Fig. 1), supporting previous reports that arsenic
accumulation in hepatocytes is associated with increased hep-




















Fig. 1. The eﬀects of BSO (c-GCS inhibitor), EA (GST inhibitor), and MK-5
hepatocytes. Cells were exposed to iAs(III) (10 lM) for 48 h in the absence or
or 100 lM). BSO, EA, and MK-571 were respectively added to the culture me
Each value represents the means ± S.D. of four determinations. **, P < 0.01creased when the concentration of MK-571 was elevated. Such
an observation was in agreement with Vellonen et al.’s report
[19] that MK-571 interferes with MTT assay in cells, leading to





71 (MRP antagonist) on arsenic-induced cytotoxicity in primary mouse
presence of BSO (0.5 or 1.0 mM), EA (100 or 150 lM), or MK-571 (50
dia 6 h (BSO) or 1 h (EA andMK-571) prior to the addition of iAs(III).
.
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of protein expression in total hepatocyte protein lysate and a
translocation to the nucleus (Fig. 2). Under these conditions,
among the proteins regulated by Nrf2, HO-1, GSTA1, c-
GCS heavy subunit (c-GCSH), c-GCS light subunit (c-GCSL),
and MRP1 were upregulated by exposure to SFN, whereas few
appreciable changes in GSTA4, GSTM1, and GSTP1 levels
were seen. Note that expression of CYT19 catalyzing oxidative
methylation of iAs(III) [20] was not aﬀected by treatment with
SFN.
If c-GCS subunits are induced by SFN, intracellular GSH
concentration should be elevated because this protein is known
to be a rate-limiting enzyme for GSH synthesis. While GSH
concentration in primary mouse hepatocytes without SFN
exposure was 93.5 ± 2.9 nmol/mg protein (n = 3), cellular
GSH levels increased by approximately 1.56-fold 24 h after















0 1 2.5 5
** **
**
Fig. 3. Enhancement of intracellular GSH by SFN in primary mouse
hepatocytes. Cells were incubated with the indicated concentrations of
SFN for 24 h. Each value represents the means ± S.D. of three









































Fig. 4. Eﬀect of SFN on cellular arsenic accumulation and cytotoxicity of iA
DMSO (0.1%) or SFN (5 lM) for 24 h prior to exposure with 5 lM iAs(III) fo
(B) Cells were exposed with either DMSO (0.1%) or SFN (5 lM) for 24 h
percentages of the control value. Each value represents the means ± S.D. ofBecause SFN was capable of elevating proteins such as c-
GCS subunits, GST isozymes, and MRP1, all of which are
responsible for facilitation of iAs(III) excretion extracellularly,
we investigated the eﬀects of SFN on steady-state levels of ar-
senic and on iAs(III)-mediated cytotoxicity. Pretreatment with
SFN (5 lM) for 24 h prior to 5 lM iAs(III) exposure resulted
in a signiﬁcant reduction of cellular accumulation of arsenic
(66.8% of control) (Fig. 4A). These results suggest that SFN
could inhibit iAs(III)-mediated cytotoxicity through decreased
arsenic levels in hepatocytes. Consistent with this notion, SFN
had a signiﬁcant protective eﬀect on arsenic cytotoxicity
(Fig. 4B).4. Discussion
It has been shown that as a chemopreventive agent, SFN
is capable of diminishing the cytotoxicity of organic chemi-
cals [11] such as menadione, tert-butyl hydroperoxide, and
4-hydroxynonenal. This function is thought to be due to
activation of Nrf2, leading to transcriptional induction of
drug-metabolizing enzymes and of MRP1 [21,22], which
are associated with detoxiﬁcation of organic chemicals. For
example, an active metabolite of aﬂatoxin B1 is conjugated
with GSH by GST isoforms and then translocated to extra-
cellular space through ABC transporters, such as the MRP
family [23]. Although these reports showed that SFN de-
creases cytotoxicity induced by organic chemicals, whether
SFN aﬀects cytotoxicity induced by inorganic chemicals re-
mained to be elucidated. In the case of arsenic, it has been
reported that iAs(III) readily undergoes GSH conjugation to
yield As(SG)3, which is pumped out to extracellular space
through MRP1 [4]. Once the GSH adduct of arsenic is
formed, cellular GSH should be consumed. Thus, we postu-
lated that increased protein levels of c-GCS, GST isoforms,
and MRP1 during pretreatment with a Nrf2 activator such
as SFN would facilitate decreased arsenic accumulation in
primary mouse hepatocytes, leading to substantial reduction
of cytotoxicity. Consistent with this notion, blockage of
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s(III) in primary mouse hepatocytes. (A) Cells were exposed with either
r 24 h. Each value represents the means ± S.D. of three determinations.
prior to the indicated concentrations of iAs(III). Data are shown as
six determinations. **, P < 0.01.
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whereas upregulation of these proteins by pretreatment with
SFN suppressed such a toxic action. These results suggest
that Nrf2 activators are eﬃcient in diminishing the cellular
toxicity of iAs(III) through transcriptional induction of pro-
teins responsible for its GSH conjugation and excretion into
extracellular space. However, it should be noted that alter-
native functions of SFN (e.g., inhibition of iAs(III) uptake)
and abolishment of the SFN eﬀect on primary hepatocytes
from Nrf2-deﬁcient mice remain to be elucidated.
We reported previously that arsenic is capable of activating
Nrf2, thereby upregulating antioxidant proteins (heme oxygen-
ase-I, peroxiredoxin I and A170) and phase II proteins
(c-GCS, NQO1) [24,25]. Also, Liu et al. showed that arsenic
induced GST and MRP expressions [18]. These reports suggest
that by increasing levels of proteins responsible for excretion of
arsenic into extracellular space, arsenic-mediated Nrf2 activa-
tion is one protective response against arsenic. To assess the
capacity of SFN to act as a chemopreventive agent for ar-
senic-induced cytotoxicity, we attempted in this study to use
this Nrf2 activator instead of arsenic itself. Our study suggests
that SFN is a naturally occurring chemical that is able to
diminish cellular arsenic levels and thus reduce its cytotoxicity.Acknowledgements: We thank Drs. Ken Itoh and Masayuki Yamam-
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